Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.

She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on 

Articles

The FDA issued a complete response letter for sotagliflozin (Zynquista) as an adjunct to insulin therapy for glycemic control.

FDA Rejects Sotagliflozin for Type 1 Diabetes; Lexicon Shifts Focus

Laura is the vice president of content for The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®’s parent company, MJH Life Sciences®, since 2011.

She has an MA in business and economic reporting from New York University. You can connect with Laura on 

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

Weight Loss Drug Tirzepatide Now Approved for Sleep Apnea in Adults With Obesity

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

FDA Approves Encorafenib With Cetuximab and mFOLFOX6 for Metastatic CRC

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

The FDA granted approval to Steqeyma (ustekinumab-stba) for inflammatory conditions, making it the seventh biosimilar to reference Stelara after a year of multiple ustekinumab biosimilar approvals.

FDA Approves Seventh Ustekinumab Biosimilar to Reference Stelara

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Gastroenterology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Lung Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Idiopathic Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Early Angiotensin Converting Enzyme Inhibition in Patients after Myocardial Infarction

Cardiovascular Protective Effects of Angiotensin Converting Enzyme Inhibitors

Current Trends and Future Prospects in the Pharmacologic Management of Hypertension

Do All Patients Deserve Treatment with Angiotensin Converting Enzyme Inhibitors after Myocardial Infarction?  An Argument to Treat only High-Risk Patients